Drug intelligence / Profile preview

ANG031

Development stage: Preclinical
Lead developer: Anagram Therapeutics
Modality: Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
Administration: Oral

Overview

ANG031 is an orally delivered enzyme therapeutic being developed by Anagram Therapeutics for the treatment of Congenital Carbohydrate Malabsorption. The drug is engineered to replace or supplement deficient carbohydrate-digesting enzymes in the gastrointestinal tract, facilitating the breakdown of specific carbohydrates and preventing their accumulation, which otherwise leads to toxic complications and malabsorption symptoms. It is currently in the preclinical stage of development and leverages Anagram's proprietary enzyme technology to address rare nutrient metabolism disorders.

Targets

LCT (Lactase-phlorizin hydrolase)

Beyond the preview

Go deeper on ANG031.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ANG031.

Explore the full profile